Find current news and media publications about Zyagnum here.
Wirtschaftswoche: Cell of Profit
20.05.2019
In the lastest edition of “Wirtschaftswoche (WiWo)” we have been mentioned. You can find the entire article over here: To the article © Handelsblatt GmbH. All Rights reserved.
Zyagnum company of the year 2018
28.09.2018
District Administrator Klaus Peter Schellhaas at the presentation of the certificate “Unternehmen des Jahres 2018” about Zyagnum: “An example of outstanding innovations, useful for many people, paired with a well thought-out sales structure is provided by Zyagnum AG in Pfungstadt. Serious illnesses like cancer can affect you in every stage of your life. Screening procedures […]
Zyagnum supports children in need in Thailand
06.02.2018
Together with the GESINAS Foundation, Zyagnum supports the expansion of the kindergarten in the Ban Nam Som School in Thailand. Thanks to this donation and the tireless commitment of Werner Luttmann (Immunotools) in the foundation, the construction of the kindergarten in Wat Chan has already been completed. For more information click here and here or: Facebook Raintree FoundationFacebook Thai […]
Validation EDIM blood test in Tübingen started
04.07.2017
The EDIM test was established at the University of Tübingen under Prof. Handgretinger, Medical Director General Paediatrics, Haematology / Oncology Children’s hospital Tübingen. Since then, samples of patients with various tumors have been examined daily. It has been shown that the EDIM test has previously identified all tumors, regardless of the tumor entity, and is characterized by […]
Universal cancer test: meaning and function of used marker TKTL1 has been clearly demonstrated
04.07.2017
In the EDIM detect, the markers TKTL1 and Apo10 are used. Both biomarkers detect fundamental biophysical mechanisms that are significantly altered in all forms of malignancy (Grimm et al., 2013). All forms of tumour cells exhibit a disorder in the process of the planned cell death (apoptosis). Only when this process is disturbed and as […]